Insider · CIK 0001131399

GSK plc

Reports to the SEC for 40 companies · BRENTFORD MIDDLESEX, X0

sec.gov

Transactions

Companies

Filings

CIK

0001131399

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-12-11	WVEWave Life Sciences, Inc.P Purchase	10% Owner	PPurchase	+1.47M sh	$19.00	+$27.9M	18,245,691
2024-09-27	WVEWave Life Sciences, Inc.P Purchase	10% Owner	PPurchase	+2.79M sh	$8.00	+$22.3M	16,775,691
2023-12-07	WVEWave Life Sciences, Inc.P Purchase	10% Owner	PPurchase	+3.3M sh	$5.00	+$16.5M	13,983,761
2022-09-16	TBPHTheravance Biopharma, Inc.J Other	Former 10% Owner	JOther	−9.64M sh	$9.75	−$94M	0
2022-09-16	TBPHTheravance Biopharma, Inc. · Exchangeable Senior Notes due 2023J Other	Former 10% Owner	JOther	—	—	—	0
2021-07-02	CVRXCVRx, Inc.C Conversion	10% Owner	CConversion	+14.9K sh	—	—	61,212
2021-07-02	CVRXCVRx, Inc. · Series F-2 Preferred StockC Conversion	10% Owner	CConversion	−1.08M sh	—	—	0
2021-07-02	CVRXCVRx, Inc.C Conversion	10% Owner	CConversion	+27.3K sh	—	—	96,937
2021-07-02	CVRXCVRx, Inc. · Series D-2 Preferred StockC Conversion	10% Owner	CConversion	−590K sh	—	—	0
2021-07-02	CVRXCVRx, Inc. · Series E-2 Preferred StockC Conversion	10% Owner	CConversion	−331K sh	—	—	0
2021-07-02	CVRXCVRx, Inc.C Conversion	10% Owner	CConversion	+636K sh	—	—	732,583
2021-07-02	CVRXCVRx, Inc.C Conversion	10% Owner	CConversion	+13K sh	—	—	46,295
2021-07-02	CVRXCVRx, Inc.C Conversion	10% Owner	CConversion	+8,380 sh	—	—	69,592
2021-07-02	CVRXCVRx, Inc.P Purchase	10% Owner	PPurchase	+275K sh	$18.00	+$4.95M	1,007,583
2021-07-02	CVRXCVRx, Inc. · Series B-2 Preferred StockC Conversion	10% Owner	CConversion	−59.5K sh	—	—	0
2021-07-02	CVRXCVRx, Inc. · Series C-2 Preferred StockC Conversion	10% Owner	CConversion	−513K sh	—	—	0
2021-07-02	CVRXCVRx, Inc. · Series G Preferred StockC Conversion	10% Owner	CConversion	−10.1M sh	—	—	0
2021-07-02	CVRXCVRx, Inc.C Conversion	10% Owner	CConversion	+1,505 sh	—	—	33,316
2021-06-21	LYELLyell Immunopharma, Inc. · Series AA Preferred StockC Conversion	10% Owner	CConversion	−30.3M sh	—	—	0
2021-06-21	LYELLyell Immunopharma, Inc.C Conversion	10% Owner	CConversion	+30.3M sh	—	—	30,253,189
2021-05-20	INVAInnoviva, Inc.S Sale	10% Owner	SSale	−32M sh	$12.25	−$392M	0
2021-02-17	Decibel Therapeutics, Inc.C Conversion	Director	CConversion	+247K sh	—	—	705,811
2021-02-17	Decibel Therapeutics, Inc.C Conversion	Director	CConversion	+458K sh	—	—	458,487
2021-02-17	Decibel Therapeutics, Inc.Series D Preferred StockC Conversion	Director	CConversion	−1.74M sh	—	—	0
2021-02-17	Decibel Therapeutics, Inc.Series C Preferred StockC Conversion	Director	CConversion	−3.13M sh	—	—	0
2021-02-17	Decibel Therapeutics, Inc.P Purchase	Director	PPurchase	+150K sh	$18.00	+$2.7M	1,183,663
2021-02-17	Decibel Therapeutics, Inc.C Conversion	Director	CConversion	+328K sh	—	—	1,033,663
2021-02-17	Decibel Therapeutics, Inc.Series A Preferred StockC Conversion	Director	CConversion	−7.12M sh	—	—	0
2020-07-24	GENOCEA BIOSCIENCES, INC.P Purchase	10% Owner	PPurchase	+1.26M sh	$2.25	+$2.84M	4,626,389
2020-07-24	GENOCEA BIOSCIENCES, INC.WarrantP Purchase	10% Owner	PPurchase	+1.26M sh	$0.13	+$158K	1,260,504
2020-07-21	Pandion Therapeutics, Inc.Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.78M sh	—	—	0
2020-07-21	Pandion Therapeutics, Inc.Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−7.85M sh	—	—	0
2020-07-21	Pandion Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+361K sh	$18.00	+$6.5M	2,248,304
2020-07-21	Pandion Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+348K sh	—	—	1,887,193
2020-07-21	Pandion Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+1.54M sh	—	—	1,538,724
2020-07-17	Pandion Therapeutics, Inc.Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+14K sh	—	—	13,997
2020-07-15	BCYCBICYCLE THERAPEUTICS PLCS Sale	10% Owner	SSale	−3,069 sh	$19.40	−$59.5K	1,910,609
2020-07-15	BCYCBICYCLE THERAPEUTICS PLCS Sale	10% Owner	SSale	−78 sh	$19.25	−$1,501.5	1,910,531
2020-07-14	BCYCBICYCLE THERAPEUTICS PLCS Sale	10% Owner	SSale	−1,597 sh	$19.27	−$30.8K	1,913,678
2020-07-14	NKTXNkarta, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.99M sh	—	—	0
2020-07-14	NKTXNkarta, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−6.34M sh	—	—	0
2020-07-14	NKTXNkarta, Inc.C Conversion	Director, 10% Owner	CConversion	+1.71M sh	—	—	2,317,399
2020-07-14	NKTXNkarta, Inc.P Purchase	Director, 10% Owner	PPurchase	+833K sh	$18.00	+$15M	3,150,732
2020-07-14	NKTXNkarta, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−293K sh	—	—	0
2020-07-14	NKTXNkarta, Inc.C Conversion	Director, 10% Owner	CConversion	+525K sh	—	—	604,589
2020-07-14	NKTXNkarta, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+10.7K sh	—	—	10,700
2020-07-14	NKTXNkarta, Inc.C Conversion	Director, 10% Owner	CConversion	+79.1K sh	—	—	79,090
2020-06-22	TBPHTheravance Biopharma, Inc. · Exchangeable NoteS Sale	Former 10% Owner	SSale	—	—	—	0
2020-05-21	Turning Point Therapeutics, Inc.P Purchase	Director	PPurchase	+83.3K sh	$60.00	+$5M	2,253,660
2020-05-20	PGNYProgyny, Inc.S Sale	10% Owner	SSale	−4M sh	$25.75	−$103M	6,238,244

Recent filings

Accepted (ET)
Dec 154
GSK plc0001999371-25-020336
SEC(opens sec.gov)
Oct 14
GSK plc0001999371-24-012789
SEC(opens sec.gov)
Jan 304
GSK plc0001999371-24-001192
SEC(opens sec.gov)
Sep 204
GSK PLC0001387131-22-009897
SEC(opens sec.gov)
Jul 64
GLAXOSMITHKLINE PLC0001387131-21-007179
SEC(opens sec.gov)
Jun 234
GLAXOSMITHKLINE PLC0001387131-21-006822
SEC(opens sec.gov)

Companies

Address

980 GREAT WEST ROAD

BRENTFORD MIDDLESEX, X0, TW8 9GS